Quick Answer
BIO-TECHNE Corp reported Revenue (ASC 606) of $1.22 billion for fiscal year 2025.
BIO-TECHNE Corp Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $1.22B | +5.2% |
| 2024 | $1.16B | +2.0% |
| 2023 | $1.14B | +2.8% |
| 2022 | $1.11B | +18.7% |
| 2021 | $931.03M | +26.0% |
| 2020 | $738.69M | +3.5% |
| 2019 | $714.01M | +11.0% |
| 2018 | $642.99M | +14.2% |
| 2017 | $563.00M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $295.88M | -0.4% | +3.3% |
| September 30, 2025 | $286.56M | -1.0% | -9.4% |
| March 31, 2025 | $316.18M | +4.2% | +6.4% |
| December 31, 2024 | $297.03M | +9.0% | +2.6% |
| September 30, 2024 | $289.46M | +4.5% | -4.6% |
| March 31, 2024 | $303.43M | +3.2% | +11.3% |
| December 31, 2023 | $272.60M | +0.4% | -1.6% |
| September 30, 2023 | $276.94M | +2.7% | -5.9% |
- BIO-TECHNE Corp showed an increase of +5.2% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2017–2025 period, BIO-TECHNE Corp’s revenue (asc 606) has grown by 116.6% (from $563.00 million to $1.22 billion).
- The most recent figure is from BIO-TECHNE Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on August 22, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: